HMGA1 proteins belong to a family of nonhistone chromatin proteins able to bind DNA in AT-rich regions and to interact with various transcription factors thus enhancing or inhibiting gene transcription by acting as architectural proteins. Although their expression is very low or absent in many adult tissues, HMGA1 proteins have been frequently found to be upregulated in human cancers and are expressed at high levels during embryogenesis, suggesting they could have a role in highly proliferating cells. We have previously demonstrated that HMGA1 expression in primary breast cancer and mammary carcinoma derived cell lines inversely correlated with BRCA1 expression and that HMGA1 is able to downregulate the expression of BRCA1 gene by binding directly to its promoter region. Being BRCA1 protein expression strictly linked to the DNA repair activity of the cell, we investigated whether HMGA1 expression was able to influence cellular responses to DNA damage. Here, we report that high expression levels of HMGA1 proteins in MCF-7 or mouse embryonic stem cells results in diminished BRCA1 expression and enhanced sensitivity to Cisplatin and Bleomycin. The increased DNA damageinduced cell death in HMGA1-expressing cells is likely due to a diminished cellular DNA repair activity. Therefore, we propose that high expression of HMGA1 protein in human malignant neoplasias, acting on BRCA1 expression, could contribute to the progression of malignant transformation influencing the response of the cells to the damaged DNA.
Introduction
HMGA1a and HMGA1b are structural nonhistone chromatin proteins encoded by a unique gene through an alternative splicing mechanism. Both isoforms are able to bind DNA in AT-rich regions and interact with various transcription factors to enhance or inhibit gene transcription by acting as architectural proteins (Reeves and Beckerbauer, 2001) . HMGA1 proteins are abundant during embryogenesis, but they are present only at low levels in normal adult tissues (Chiappetta et al., 1996) . Induction of HMGA1 expression occurs in several human malignant neoplasias including thyroid (Chiappetta et al., 1998) , breast , prostate (Tamimi et al., 1993) , and ovary (Masciullo et al., 2003) carcinomas. Increased expression of the HMGA1 gene has been demonstrated in mouse (Ram et al., 1993) and human (Liu et al., 1999) breast carcinoma derived cell lines, with a direct correlation between HMGA1 protein levels and the metastatic phenotype of human breast cancer cell lines (Liu et al., 1999) .
Inhibition of HMGA protein synthesis prevented the neoplastic transformation induced by the myeloproliferative sarcoma virus or by the Kirsten murine sarcoma virus (Berlingieri et al., 1995) and caused death in several carcinoma cell lines (Scala et al., 2000) , suggesting that HMGA overexpression plays a key role in the induction of the malignant phenotype.
We have previously reported that HMGA1b protein binds both in vitro and in vivo to the human and mouse BRCA1 promoters, thus inhibiting their activity, and that HMGA1 overexpression results in the downregulation of BRCA1 mRNA and protein in human mammary carcinoma cell lines as well as in mouse embryonic stem (ES) cells . Moreover, a correlation was found between HMGA1 protein levels and BRCA1 mRNA expression both in primary breast tumors and breast cancer-derived cell lines, suggesting that HMGA1 protein overexpression may have a role in the BRCA1 downregulation observed in aggressive mammary carcinomas . Since BRCA1 protein is involved in DNA repair following several types of DNA damage (Scully and Livingston, 2000) , we investigated whether there was a correlation between HMGA1 expression and cell sensitivity to DNA-damaging agents. It has been proposed that a link exists between BRCA expression and cis-platinum (cisplatin) sensitivity since exposure to cisplatin determines the upregulation of BRCA1 mRNA expression in mammary carcinoma cells (Andres et al., 1998) and BRCA1 protein levels positively correlate with cisplatinresistance in breast and ovary carcinoma cells (Husain et al., 1998) . More recently, the BRCA1-FANCONI anemia pathway function has been strictly correlated with the onset of cisplatin resistance in ovary carcinomas (Taniguchi et al., 2003) . Finally, Brca1 null mouse ES cells are more sensitive to cisplatin as compared to their normal counterpart (Bhattacharyya et al., 2000) . Therefore, we investigated the role of HMGA1 protein following cisplatin-induced DNA damage, both in the breast carcinoma cell line MCF-7 overexpressing the HMGA1b protein and in ES cells null for the Hmga1 gene.
Using these experimental model systems, we demonstrate that HMGA1 expression induces an enhanced apoptosis rate and a decreased cell survival following exposure to DNA-damaging agents, likely diminishing the expression levels of BRCA1 protein.
Results

ES cells null for the Hmga1 gene are less sensitive to cisplatin with respect to the wild-type ES cells
Mouse ES cells express very high levels of HMGA1 mRNA and protein , making the ES cells knocked-out in both the Hmga1 gene alleles a useful tool to evaluate the role of HMGA1 proteins in several experimental conditions Battista et al., 2003) . In mouse ES cells, deletion of both the Brca1 alleles results in a fivefold higher sensitivity to the DNA crosslinking agent cisplatin compared to the wild-type cells (Bhattacharyya et al., 2000) . Therefore, we first used ES cells to investigate the role of HMGA1 protein following cisplatin-induced DNA damage. Wildtype (WT) mouse ES cells exposed to 5, 10, 25 mM cisplatin or vehicle for 1 h in serum-free medium were allowed to recover in complete medium for 2 h and, then, the expression of Brca1 and Hmga1 gene products was evaluated by Western blot (Figure 1a and c), RT-PCR ( Figure 1b ) and Northern blot (Figure 1d ). BRCA1 mRNA and protein levels increased about twofolds in cells treated with 25 mM cisplatin and these increases were accompanied by a significant reduction of HMGA1 protein levels ( Figure 1a) . However, the Hmga1 mRNA expression did not significantly change (Figure 1d ), suggesting that post-transcriptional or posttranslational modifications contributed to cisplatininduced downregulation of HMGA1 protein levels. As expected, we observed a 2.5-fold increase of Brca1 expression in Hmga1 Subsequently, we evaluated the apoptotic rate of cisplatin-treated ES cells by analysing the cleavage of the poly ADP-ribose polymerase protein (PARP), which represents a critical molecular event when cells undergo apoptosis (Soldani and Scovassi, 2002) . Exposure of WT ES cells to 25 mM cisplatin resulted in the cleavage of PARP protein, as revealed by the presence of the 85-kDa band corresponding to a cleaved form of PARP, whereas only the major band of 112 kDa, corresponding to the uncleaved PARP protein, was detected in Hmga1 À/À ES cells after the same treatment (Figure 1e ), suggesting that ES cells unable to express the HMGA protein are more resistant to cisplatininduced apoptosis.
FACS analysis of DNA content of ES cells treated with cisplatin confirmed the different cisplatin sensitivity between WT and Hmga1 À/À cells ( Figure 2a ). In this experiment, the ES cells were treated for 1 h with 10 or 25 mM cisplatin and analysed after 6, 12 and 24 h. WT ES cells accumulate in S phase 6 h after treatment and in G2/M phase after 12 h. After 24 h, cells restart to cycle or undergo apoptosis as indicated by their accumulation in sub-G1 phase of the cell cycle. These effects were dose-dependent since the percentage of apoptotic cells was 2475 and 4174% for 10 and 25 mM cisplatin, respectively. In contrast, although Hmga1 À/À ES cells accumulate with similar extent in S and in G2/M phase at 6 and 24 h post-treatment, they failed to undergo apoptosis. In fact, only a small percentage of cells was found in the sub-G1 population after 48 h (873 and 2476% for 10 and 25 mM, respectively), demonstrating a statistically significant lower presence of sub-G1 cells population (Po0.01 for both 10 and 25mM treatments with respect to WT cells using the Student's t-test). Next, WT and Hmga1 À/À ES cells were treated with increasing amount of cisplatin (2.5, 5, 10 and 25 mM), and their ability to survive this treatment was evaluated. Accordingly with FACS analysis, WT cells resulted twofold more sensitive to cisplatin with respect to the Hmga1 null cells (Figure 2b ).
Hmga1
À/À ES cells show a higher DNA integrity compared to the WT ES cells after cisplatin treatment
On the basis of these results, we investigated the extent of damaged DNA in Hmga1 WT and null cells using the single-cell gel electrophoresis COMET assay. The assay is based upon the ability of denatured cleaved DNA fragments to migrate out of the cell nucleus under the influence of an electric field, while the undamaged DNA remains within the nucleus. Thus, only undamaged nuclei retain their round shape when visualized by fluorescence microscopy (Figure 3a) . Although cisplatin forms DNA adducts and the formation of the tail is less evident with respect to other treatments like cellular irradiation, this assay has been successfully used to identify cisplatin damaged cells (Buschfort-Papewalis et al., 2002) . To quantify the DNA damage induced by cisplatin in this system, we evaluated the percentage of damaged cells identified by the loss of the round-shape nuclear morphology (Figure 3a) . Cells treated or not with 10 mM cisplatin were allowed to repair the DNA for 6 h in complete medium and then processed for the COMET assay. The statistical analysis clearly demonstrated a higher number of damaged cells in WT respect to Hmga1 À/À cells ( Figure 3b ). Moreover, we observed that the distance between the nucleoid and the migrating DNA was consistently higher in WT with respect to Hmga1 null ES cells suggesting the possibility that qualitative differences in DNA repair activity exist between the WT and Hmga1 À/À ES cells.
MCF-7 cells overexpressing the HMGA1 protein are more sensitive to cisplatin than the parental cells
It has been previously published that the MCF-7 cells resistant to cisplatin displayed higher levels of BRCA1 compared to parental cells and that the original sensitivity could be restored by decreasing the BRCA1 levels (Husain et al., 1998) , supporting the idea that BRCA1 protein plays a role in the response to cisplatininduced DNA damage in mammary carcinoma cells.
We treated parental and HMGA1b stable transfected MCF-7 cells, which showed a decrease in BRCA1 protein levels (Figure 4a) , with increasing doses of cisplatin and, subsequently, analysed their survival in a cell survival assay. Both the MCF-7 cell clones overexpressing HMGA1b (MCF-7YHA6 and 7) were more sensitive with respect to parental cells to cisplatin treatment (Figure 4b ). FACS analysis of cell cycle distribution revealed that 24 h after cisplatin exposure, higher percentage of HMGA1b overexpressing cells accumulate at the onset of S phase with respect to parental cells (Figure 4c) . At 72 h after treatment, we observed a slight increase in the sub-G1 population in MCF-7 HMGA1b cells with respect to parental (MCF-7 3.0%, MCF-7YHA6 6.2%, MCF-7YHA7 7.9%), thus supporting the data obtained with the survival assay. Moreover, MCF-7YHA6 and 7 cell clones exposed for À/À ES cells exposed to the indicated amounts of cisplatin. A mean (7s.d.) of three independent experiments (each performed in duplicate) is reported 24 h to increasing concentrations of cisplatin, displayed a greater number of apoptotic cells with respect to parental MCF-7 cells in a dose-dependent manner, as evaluated by the TUNEL assay (Figure 5a and b) .
Using the short interference (siRNAs) technology, we next assayed whether the reduction of BRCA1 protein levels could result in an altered response of MCF-7 cells to cisplatin treatment. Treatment of MCF-7 with a pool of siRNAs targeting the human BRCA1 mRNA was able to reduce the BRCA1 protein levels whereas control siRNAs did not have any effect on the BRCA1 protein levels (Figure 6a) . Importantly, the block of BRCA1 protein synthesis resulted in an increased sensitivity of MCF-7 cells to cisplatin treatment comparable to the effect of HMGA1 overexpression in the same cells. Impaired BRCA1 expression, by specific siRNAs treatment, determined a higher accumulation of MCF-7 cells at the G1-S transition after 24 h exposure to 5 or 10mM cisplatin when compared to control treated cells (Figure 6b ), demonstrating that in MCF-7 cells reduced expression of BRCA1 or HMGA1 overexpression caused comparable alterations at the G1-S cell cycle transition (compare Figures 4c and 6b) . Moreover, the cell survival assay demonstrated that in MCF-7 cells, BRCA1 downregulation by siRNA resulted in a decreased survival of cisplatin-treated cells (Figure 6c ). Yet, the reduced BRCA1 expression had no effect on cell survival in untreated cells (9277% formed colony for BRCA1 with respect to control siRNAs). These results point to the regulation of BRCA1 expression as an important determinant of mammary carcinoma cells sensitivity to cisplatin.
In order to test whether the effects of HMGA1 overexpression on cell survival and on cell cycle progression in MCF-7 were due to an improper response to the damaged DNA through BRCA1 regulation, we treated the cells with bleomycin a radiomimetic antibiotic known to generate DNA double-strand breaks and, therefore, to induce BRCA1-dependent DNA repair. As control, we also treated MCF-7 cell clones with taxol, a drug that decreases cells survival acting on the microtubules network, thus determining accumulation of the cells at the G2/M transition and subsequent cell death. MCF-7YHA6 and 7 cell clones were more sensitive to bleomycin with respect to parental MCF-7 (Figure 7) . In sharp contrast, taxol treatment caused similar effects both in cell cycle distribution and cell survival in parental and MCF-7 HMGA1-expressing cells (data not shown), supporting a primary role for HMGA1 in response to damaged DNA. In fact, treatment of MCF-7 cells for 24 h with 10 or 25 mg/ml of bleomycin demonstrated that while parental cells were blocked in G1 in a dose-dependent manner (7875 and 8373 of G1 population for 10 and 25 mg/ml, respectively) MCF-7YHA7 cells failed to accumulate in G1 at comparable extent (6572 and 6374 of G1 population for 10 and 25 mg/ml, respectively) (Figure 7a ), suggesting a defect for these cells to respond properly to DNA-damaging agents. Moreover, MCF-7YHA7 cells demonstrated a lower survival to bleomycin in the cell survival assay when compared to parental MCF-7 cells (Figure 7b) , confirming a role for HMGA1 in the sensitivity of these cells to DNA-damaging agents.
It has been reported that BRCA1 expression is necessary for the proper relocalization of Rad-51 protein to nuclear foci following either cisplatin (Bhattacharyya et al., 2000) or bleomycin treatment (Quinn et al., 2003) . Thus, we analysed by immunofluorescence the localization of Rad-51 in MCF-7, MCF-7YHA6 and MCF-7YHA7 cells exposed for 2 h to bleomycin (Figure 8a ) or cisplatin (Figure 8b) , and then washed and cultured in complete medium for additional 6 h. HMGA1 overexpression drastically inhibited Rad-51 nuclear foci localization in MCF-7 cells after both bleomycin and cisplatin treatment (Figure 8a and b) , an event that occurred in a time- (Figure 8c ), supporting the hypothesis that HMGA1 could impair the cell ability to repair DNA through the interference with the BRCA1 pathways.
We have also observed that after exposure to cisplatin (Figure 4 ) or to bleomycin (Figure 7) , MCF-7 cells overexpressing HMGA1 failed to block at the G1/S transition at the same extent of parental cells. The proper G1/S checkpoint regulation following DNA damage is mainly due to the p53-mediated induction of p21 waf1 and it has been proposed that BRCA1 expression is necessary for p53 and p21 induction following ionizing radiation (Fabbro et al., 2004) , suggesting that the absence of BRCA1 could influence the G1/S cell cycle progression after DNA damage (Fabbro et al., 2004) . We thus evaluated the expression of p21 and p53 in parental and YHA6 and 7 MCF-7 cells untreated or exposed for 24 h to cisplatin or bleomycin. The expression of p21 and p53 in untreated cells is not significantly modified by HMGA1 expression (Figure 9a and b) . After exposure to bleomycin and cisplatin, p21 and p53 are both readily increased in parental cells (Figure 9a, lanes 1-5) . Densitometric scanning of the blots revealed that both bleomycin and cisplatin induced a drastic increase in p21 expression (Figure 9b, upper graph) . Similarly, p53 protein was readily upregulated after bleomycin and cisplatin treatment (Figure 9b, lower graph) . Conversely, only a slight increase in p21 expression was observed in MCF-7 YHA6 and 7 cells following bleomycin treatment, and there was no increase at all after cisplatin treatment (Figure 9a and b) . Moreover, p53 expression was only 
Discussion
Several functions are attributed to the HMGA proteins since they can interact with a variety of transcription factors interfering with their activities and thus regulating the expression of several genes (see Reeves and Beckerbauer (2001) for a review of the literature).
Here, we report that HMGA1 proteins participate in the regulation of the pathways involved in the DNA repair following cisplatin treatment, demonstrating that Hmga1 null ES cells are more resistant to cisplatininduced DNA damage, and that, on the opposite, overexpression of HMGA1 in MCF-7 cells results in an increased cisplatin sensitivity. It is noteworthy that BRCA1 induction after cisplatin exposure requires the downregulation of Hmga1 gene, at least in ES cells, suggesting the existence of a tight relationship between HMGA1 and BRCA1 expression and cisplatin sensitivity. It is to note that HMGA proteins do not regulate gene expression directly but contribute to the activity of a variety of transcription factors and, thereby, act as fine-tuning regulators of gene expression. Accordingly, the quantitative differences in the levels of BRCA1 and in the sensitivity to cisplatin between WT and Hmga1 In MCF-7 cells overexpressing HMGA1b protein, the diminished expression of BRCA1 protein is accompanied by the inappropriate relocalization of the Rad-51 protein to nuclear foci, further suggesting that the higher damage sensitivity observed in HMGA1 expressing cells is dependent on the diminished BRCA1 expression. In agreement, it has been recently demonstrated that the reduced expression of Rad-51 impairs cell response to DNA damage induced by cisplatin (Ito et al., 2005) . The similar effects exerted by HMGA1 overexpression and BRCA1 downregulation on cisplatintreated MCF-7 cells (Figures 4 and 6 ) support our hypothesis that HMGA1 proteins influence the response to DNA damage mainly by acting on BRCA1 expression. This hypothesis is further sustained by the higher sensitivity of HMGA1 -expressing MCF-7 cells to the radiomimetic antibiotic bleomycin. Moreover, in MCF-7 cells expressing high levels of HMGA1 the exposure to the DNA-damaging agents caused an incomplete activation of p53 and p21, thus resulting in an improper cell cycle progression through the G1/S phase. This observation could be related to the notion that BRCA1 is necessary for the proper induction of p21 and the consequent G1/S cell cycle arrest after DNA damage caused by ionizing radiation (Fabbro et al., 2004) . It is possible that in HMGA1-overexpressing cells, the diminished expression of BRCA1 interferes with RAD51 relocalization to nuclei foci and with p53-p21 upregulation, eventually resulting in a lower response to DNA-damaging agents and enhanced apoptosis. However, it cannot be excluded that HMGA1 protein may interfere with this function also through other mechanisms like chromatin bending and/or the interaction with other proteins involved in the DNA repair. Interestingly, HMGA1 gene is overexpressed in human prostate cancers (Tamimi et al., 1993) and its expression positively correlates with the extent of chromosomal rearrangements in prostate tumors derived cell lines (Takaha et al., 2002) . Intriguingly, a role as tumor suppressor has been proposed for the BRCA1 protein in this type of cancer (Rosen et al., 2001) .
It has been recently reported that BRCA1 expression enhances nucleotide excision repair (NER) in human cells (Hartman and Ford, 2002) and that its loss or downregulation leads to an initial decline in NER activity, resulting in an accumulation of additional mutations, particularly in the p53 gene. This would result in a more pronounced NER decline, with consequent supplementary mutations leading to invasive cancer (Hartman and Ford, 2002) . Substrate of the NER pathway include the DNA adducts formed from cisplatin (Reed, 1998) , supporting a role for BRCA1 in the DNA damage repair following cisplatin chemotherapy.
In conclusion, we demonstrate here that high expression levels of HMGA1 proteins in MCF-7 or mouse ES cells, result in enhanced sensitivity to cisplatin and bleomycin likely by leading to reduced BRCA1 protein levels, thus suggesting that inhibition of BRCA1 functions by high expression levels of HMGA1 proteins could represent a mechanism for cancer cells to reach a more aggressive phenotype.
Materials and methods
Cell culture
MCF-7 cells were maintained in minimum essential medium (MEM) supplemented with 10% fetal bovine serum, 2 mM sodium pyruvate, 2 mM glutamine, 100 nM insulin, 1 Â MEM nonessential amino acids, 100 IU/ml penicillin and 100 mg/ml streptomycin. Stably transfected cell lines MCF-7 CMV and were maintained in medium containing 200 mg/ml G418. For BRCA1 knockout, 200 nM of BRCA1 siRNAs or control siRNAs (Qiagen) were added to MCF-7 cells in MEM supplemented with 0.1% FBS using a siRNAs transfection kit (Gene Therapy System) following the manufacturer's instructions. After 6 h, serum was added to 10% final concentration and cells were incubated for 18 h at 371C. After 24 h, cells were treated with the indicated doses of cisplatin as described and prepared for FACS or cell survival analysis.
For cisplatin experiments, MCF-7 cells were plated in complete medium, then washed and incubated in serum-free medium (1 Â MEM nonessential amino acids, 100 IU/ml penicillin and 100 mg/ml streptomycin) with the indicated amount of cisplatin for 2 h. Cells were then harvested, counted and plated at 1000 and 2000 cells per 100 mm dish in complete medium. After 15 days, cells were stained with crystal violet and the colonies were counted.
Culture of murine ES cells
WT and Hmga1
À/À ES cells were generated and cultured as described . Before cisplatin survival assay, fibroblasts were removed, by three passages on gelatin-coated plates. Leukemia inhibiting factor (100 U/ml) was added to maintain the pluripotent undifferentiated state. ES cells were then washed and incubated in serum-free medium (1 Â DMEM nonessential amino acids, 100 IU/ml penicillin and 100 mg/ml streptomycin) with the indicted amount of cisplatin for 1 h. Cells were then harvested, counted and plated at 1000 and 2000 cells per 100 mm dish. After 15 days, cells were stained with crystal violet and the colonies were counted. Colony assay after cisplatin treatment was performed three times in duplicate for each cell concentration.
Protein extraction, Western blotting and antibodies
Cells were washed twice in ice-cold PBS and lysed in NP40 lysis buffer , supplemented with Completet protease inhibitors cocktail (Roche Diagnostic Corporation). Western blot analyses were performed as described , following standard techniques. Anti-HMGA1 were previously described or purchased from Santa Cruz Biotechnology. Antibodies against human BRCA1 included rabbit polyclonal antibodies (PharMingen). Anti-mouse BRCA1 M-20, anti-tubulin and anti Rad-51 antibodies were purchased from Santa Cruz Biotechnology. Anti-PARP was from BD Clontech. Bound antibodies were detected by the appropriate secondary antibodies and revealed with an enhanced chemiluminescence system (Amersham-Pharmacia Biotech).
Flow-cytometry
Cells were analysed for DNA content as previously described . Cisplatin-treated cells were collected at the indicated time points, washed in PBS and fixed in ethanol. DNA was stained with propidium iodide (50 mg/ml) and cells were analysed using a FACScan flow cytometer (Becton Dickinson). Cell cycle data were analysed with the XLII system program (Becton Dickinson). 
TUNEL assay
Tunel assay was performed essentially as previously described (Baldassarre et al., 1999) . Briefly, MCF-7 cells were treated with increasing doses of cisplatin and after 72 h fixed in 3% paraformaldehyde (PFA) and permeabilized with 0.2% Triton X-100 in PBS. After blocking of nonspecific sites with 0.1% BSA in PBS for 18 h at 41C, cells were stained using the 'Cell Death Detection Kit AP' (Roche) following manufacturer's instructions.
Comet assay
Cells treated or not with 10 mM cisplatin were allowed to repair the DNA for 6 h in complete medium and then processed for the COMET assay (Trevigen). Assay was performed following manufacturer's instructions. Briefly, untreated or cisplatintreated cells were suspended in low melting point agarose at a density of 1 Â 10 5 /ml at 421C and immediately 75 ml were pipetted onto a CometSlidet. Slides were incubated at 41C for at least 15 min, immersed in prechilled lysis solution for 60 min and then in alkali solution for 60 min in the dark. After two washes in TBE 1 Â , slides were transferred in a horizontal electrophoresis apparatus, covered with TBE 1 Â buffer and run for 10 min at 1 V/cm. Slides were then incubated in ethanol for 5 min, air-dried, stained with SYBRt Green and analysed with epifluorescence microscopy. Quantification was performed by counting 50 cells per slide.
Immunofluorescence analysis
MCF-7 cells were fixed in 3% PFA and then processed for immunofluorescence as previously described (Baldassarre et al., 1999) . The anti-Rad51 antibody was diluted 1 : 100 and the anti-rabbit Texas-Red or FITC-conjugated (Jackson Immunoresearch) was diluted 1 : 500. Hoechst (Sigma) staining was used to identify cell nuclei. 
